(MGTX) MeiraGTx Holdings - Ratings and Ratios

MeiraGTx Holdings plc (NASDAQ:MGTX) is a clinical-stage gene therapy company specializing in the development of innovative treatments for severe and rare diseases. The company focuses on ocular diseases, including inherited retinal diseases and large degenerative ocular disorders, as well as neurodegenerative diseases and xerostomia. Its pipeline includes multiple clinical-stage programs: Phase I/II trials for achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; a Phase I trial for radiation-induced xerostomia; and a Parkinsons disease program that has completed Phase II testing. MeiraGTx has a strategic research collaboration with Janssen Pharmaceuticals, Inc., to develop and commercialize gene therapies for inherited retinal diseases. Founded in 2015, the company is headquartered in New York, New York.

From a technical perspective, MGTX has shown moderate volatility with an Average True Range (ATR) of 0.39. The stock is currently trading at $6.98, above its 20-day simple moving average (SMA) of $6.75 but below its 50-day SMA of $6.38 and 200-day SMA of $5.32. The average 20-day trading volume is approximately 309,703 shares.

Fundamentally, MeiraGTx has a market capitalization of $570.52 million with a forward price-to-earnings (P/E) ratio of 2.52. The companys price-to-book (P/B) ratio is 5.95, and its price-to-sales (P/S) ratio is 40.96, reflecting its growth-stage valuation. The return on equity (RoE) is -92.10%, typical for a clinical-stage biotechnology company focused on research and development rather than commercial revenue.